A phase 2, proof-of-concept trial of ISM5411 in active ulcerative colitis patients
Latest Information Update: 09 Jan 2025
Price :
$35 *
At a glance
- Drugs ISM-5411 (Primary)
- Indications Ulcerative colitis
- Focus Proof of concept; Therapeutic Use
- 09 Jan 2025 New trial record
- 07 Jan 2025 According to an InSilico Medicine media release, company expects to initiate the trial in second half of 2025.